Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

MagicRon_ Sep. 1 at 4:30 PM

$ABCL LOL the state of you BullTards as if your pocket money is moving a 4 bill MC stock. Just deal with reality this is going back to $5. And get a job, dossers.

0 · Reply

Stocktradesmoon Sep. 1 at 3:55 PM

$ABCL WE ABOUT to TAKE OFF and TACKLE $12’sssss! CONSOLIDATION DONE ✅ HUGE BUY’S COMING in!! A LOT is HAPPENING with ABCL and with ABCL 575 data coming this QUARTER coming from the CEO CARL. With SEVERAL MANAGEMENT BUYING OVER $2,000,000 MILLION dollars in shares in the OPEN MARKET at $11. 1 thing is FOR SURE WE GOING MUCH HIGHER and this is JUST the BEGINNING!!!! BOOM!!! BOOM 💥!! BUY NOW JOIN US for the RIDE!!! ABCL is the #FUTURE of MEDICINE 💊

2 · Reply

Buying_Low_Selling_High Sep. 1 at 3:53 PM

$ABCL Bears are trying but its becoming harder and harder to keep it this low. Huge upwards momentum coming....

0 · Reply

Stocktradesmoon Sep. 1 at 3:21 PM

$ABCL $ABCL GET IN NOW!!! BUY..BUY..! What a gift at these prices. $13’ss-15’ss this week. Do you all UNDERSTAND that the ABCL 575 is coming OUT this QUARTER!! CARL said 575 COMING this QUARTER!!! MANAGEMENT just bought over 2 MILLION of SHARES in the OPEN MARKET at $11!! ONLY FOR 1 REASON…they KNOW SOMETHING and we ABOUT to SKYROCKET in PRICE $$15-$20’ssss plus!!!

3 · Reply

Stocktradesmoon Sep. 1 at 3:03 PM

$ABCL

0 · Reply

Stocktradesmoon Sep. 1 at 2:58 PM

$ABCL DON’T let the SHORT’s STEAL or BORROW YOUR SHARES!!! It is done consolidating going to $13-15’ss this week. SHORTS don’t know what to do they are NERVOUS!! SHORT INTEREST @ 43MILLION!!!!

0 · Reply

Stocktradesmoon Sep. 1 at 2:40 PM

$ABCL EXACTLY!!

0 · Reply

Stocktradesmoon Sep. 1 at 2:31 PM

$ABCL $ABCL GET in NOW!! Don’t stay in the SIDELINES!! CONSOLIDATION is OVER we are moving to the NEXT LEG Up $$13-15’ssssss

0 · Reply

Stocktradesmoon Sep. 1 at 2:22 PM

$ABCL VERY NICE BUY’s! $600,000 WORTH! Been CONSOLIDATING for a few day’s $12’sss COMING up. My CHART 📈 has given me the GREEN CANDLE!! It’s GO TIME $12’sss next!

0 · Reply

FGA Sep. 1 at 1:30 PM

$ABCL same BS different day! Double D's are always trying to make you sell! Patience pays in a GRAND way!

0 · Reply

AbCellera rises 17.0%

2026-08-25T14:06:36.000Z - 7 days ago

AbCellera rises 10.7%

Aug 13, 2026, 12:05 AM EDT - 19 days ago

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

2026-08-11T20:05:47.000Z - 20 days ago

AbCellera announces $200M common stock, warrants offering

Aug 11, 2026, 4:01 PM EDT - 20 days ago

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-08-11T13:35:37.000Z - 21 days ago

AbCellera price target raised to $30 from $12 at Truist

2026-08-10T19:55:32.000Z - 21 days ago

AbCellera price target raised to $25 from $13 at JonesResearch

Aug 10, 2026, 8:00 AM EDT - 22 days ago

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 7:30 AM EDT - 22 days ago

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 22 days ago

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 22 days ago

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:23 AM EDT - 22 days ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:13 AM EDT - 22 days ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

2026-08-10T11:11:27.000Z - 22 days ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

Aug 10, 2026, 7:00 AM EDT - 22 days ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 7, 2026, 4:30 PM EDT - 24 days ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

2026-08-06T12:20:50.000Z - 26 days ago

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:12:02.000Z - 26 days ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

Aug 5, 2026, 5:00 PM EDT - 26 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 26 days ago

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 26 days ago

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 26 days ago

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 26 days ago

AbCellera Reports Q2 2026 Business Results

2026-07-29T11:27:06.000Z - 4 weeks ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

Jul 29, 2026, 7:00 AM EDT - 4 weeks ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

2026-07-09T21:29:02.000Z - 7 weeks ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

Jul 7, 2026, 4:05 PM EDT - 7 weeks ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-07T10:35:14.000Z - 2 months ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

2026-07-06T13:15:29.000Z - 2 months ago

AbCellera apponts Lynn Seely to board of directors

LYEL

Jul 6, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jun 17, 2026, 7:43 AM EDT - 2 months ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jun 17, 2026, 7:00 AM EDT - 2 months ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 5, 2026, 9:00 AM EDT - 3 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 4, 2026, 11:40 AM EDT - 3 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 3 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 4 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 1, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 4 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 4 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026, 4:05 PM EDT - 5 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 6 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 7 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 7 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 8 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 8 months ago

AbCellera Biologics Slides: Corporate presentation

Jan 12, 2026, 9:00 AM EST - 8 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 9 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 9 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 10 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 10 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 1 year ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 2 years ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

MagicRon_ Sep. 1 at 4:30 PM

$ABCL LOL the state of you BullTards as if your pocket money is moving a 4 bill MC stock. Just deal with reality this is going back to $5. And get a job, dossers.

0 · Reply

Stocktradesmoon Sep. 1 at 3:55 PM

2 · Reply

Buying_Low_Selling_High Sep. 1 at 3:53 PM

$ABCL Bears are trying but its becoming harder and harder to keep it this low. Huge upwards momentum coming....

0 · Reply

Stocktradesmoon Sep. 1 at 3:21 PM

3 · Reply

Stocktradesmoon Sep. 1 at 3:03 PM

$ABCL

0 · Reply

Stocktradesmoon Sep. 1 at 2:58 PM

0 · Reply

Stocktradesmoon Sep. 1 at 2:40 PM

$ABCL EXACTLY!!

0 · Reply

Stocktradesmoon Sep. 1 at 2:31 PM

$ABCL $ABCL GET in NOW!! Don’t stay in the SIDELINES!! CONSOLIDATION is OVER we are moving to the NEXT LEG Up $$13-15’ssssss

0 · Reply

Stocktradesmoon Sep. 1 at 2:22 PM

$ABCL VERY NICE BUY’s! $600,000 WORTH! Been CONSOLIDATING for a few day’s $12’sss COMING up. My CHART 📈 has given me the GREEN CANDLE!! It’s GO TIME $12’sss next!

0 · Reply

FGA Sep. 1 at 1:30 PM

$ABCL same BS different day! Double D's are always trying to make you sell! Patience pays in a GRAND way!

0 · Reply

Rastafari Sep. 1 at 12:57 PM

$ABCL The coil is tight and loaded. The stock is going to finish in the green today. Don’t get shaken out by the pre-market drop—stay focused and hold your conviction! Remember the movement yesterday? It was a .70c swing!

1 · Reply

MagicRon_ Sep. 1 at 12:17 PM

$ABCL Good time for a short report - Ive send the lead to Hindenburg, Culpe and a few others

2 · Reply

tiddyy Sep. 1 at 5:28 AM

$ABCL Alright third times the charm guys, $13 please. Today.

0 · Reply

Rastafari Sep. 1 at 1:53 AM

$ABCL expect ABCL to regain $12 tomorrow. I am not Nostradamus, but the momentum is there.

0 · Reply

PLTRLONGDONG Sep. 1 at 1:17 AM

$ABCL this will be $25 end of year

0 · Reply

Buying_Low_Selling_High Sep. 1 at 12:44 AM

$ABCL What a dissapointing day for bears. great reversal and lesson for shorts. dips are bought by smart money.

0 · Reply

CapitalMonk Aug. 31 at 8:38 PM

$ABCL Price: $11.48 (-7.42%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±17.51% RSI: 63.7 | Momentum: Strong Momentum Volume: -52.7% vs avg Volatility: 9.42% Support: $5.57 | Resistance: $12.58 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

Rastafari Aug. 31 at 6:30 PM

$ABCL summary My ranking for ABCL’s next big partnership Regeneron > AstraZeneca > Lilly > BMS > Roche And I’d add one important wildcard: AbbVie. AbbVie is already an AbCellera partner, and the relationship was expanded in 2025 specifically to include T-cell engagers for oncology. It also continues to spend aggressively on external bispecific technology—its 2026 RemeGen deal included a $650M upfront payment and up to $4.95B in milestones. That makes AbbVie potentially the easiest company to envision doing another, larger AbCellera transaction.

0 · Reply

Rastafari Aug. 31 at 6:29 PM

$ABCL part 5 5. Roche / Genentech Roche is a slightly different proposition. It already possesses enormous internal antibody and bispecific capabilities, so it doesn’t have the same obvious need for AbCellera’s technology. But Roche also has one of the world’s largest oncology businesses, and the commercial success of bispecifics has made the modality increasingly attractive across the industry. A highly differentiated AbCellera TCE—particularly one addressing a difficult solid tumor or autoimmune target—could therefore be interesting. Probability: ~15–20%.

0 · Reply

Rastafari Aug. 31 at 6:28 PM

$ABCL part 4 4. Bristol Myers Squibb BMS is a natural candidate because of its enormous immuno-oncology business. The company has been aggressively acquiring external immunology/oncology technologies, including its $1.5 billion acquisition of Orbital Therapeutics. BMS’s recent termination of its Cellares manufacturing agreement doesn’t change my view of its appetite for external innovation; that was a manufacturing-platform issue rather than evidence that BMS is backing away from immunotherapy. Probability: ~20%.

0 · Reply

Rastafari Aug. 31 at 6:28 PM

$ABCL part 3 3. Eli Lilly and Company Lilly is becoming increasingly interesting. Just today, Lilly announced an acquisition of Merida Biosciences for up to $2.875 billion, specifically to expand into autoimmune and allergic disease. That is important because Vertex’s AbCellera deal is focused on autoimmune disease. Lilly also has the financial firepower to make a substantial platform investment. Its recent acquisition activity demonstrates that it is willing to spend heavily to expand its pipeline. And there is another strategic angle: Lilly was an early AbCellera investor, so there is already familiarity between the organizations. Probability: ~20–25%

0 · Reply

Rastafari Aug. 31 at 6:25 PM

$ABCL part 2 1. Regeneron Pharmaceuticals — my #1 This is the company I’d watch most closely. Regeneron already has substantial expertise in bispecific antibodies through its Veloci-Bi platform. In June 2026, Regeneron expanded its collaboration with CytomX around conditional bispecific cancer therapies; that expansion gives Regeneron options on additional programs and carries potential milestones of roughly $4 billion. That’s almost exactly the type of commercial behavior that makes an AbCellera deal conceivable. Why AbCellera fits: AbCellera could provide Regeneron with differentiated TCE targets, novel CD3 arms, costimulatory arms and multispecific formats without Regeneron having to build every capability internally. Probability I’d assign: ~30% of a meaningful AbCellera collaboration within the next 12–24 months.

0 · Reply

Market Cap	3.48B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	4,951,100
Avg Vol	8,325,590
Day's Range	N/A - N/A
Shares Out	306.61M
Stochastic %K	49%
Beta	1.20
Analysts	Strong Sell
Price Target	$16.12